Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.38 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | MLYCD | O95822 | 2/20 | 0.32 |
| ▸ | PDE2A | O00408 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19615785 | 0.87 | TRPV4 (0.53) | TRPV4NR1I2CYP2C9PDE2A | |
| SCHEMBL21789264 | 0.85 | IDH1 (0.34) | TRPV4 | |
| SCHEMBL17775982 | 0.85 | TRPV4 (0.36) | TRPV4NR1I2CYP2C9MLYCDPDE2A | |
| SCHEMBL12578908 | 0.84 | TRPV4 (0.37) | TRPV4 | |
| SCHEMBL14878751 | 0.83 | TRPV4 (0.35) | TRPV4NR1I2CYP2C9MLYCDPDE2A | |
| SCHEMBL14451426 | 0.81 | PTPN5 (0.36) | TRPV4NR1I2CYP2C9MLYCDPDE2A | |
| SCHEMBL30521437 | 0.81 | PTPN5 (0.36) | TRPV4NR1I2CYP2C9MLYCDPDE2A | |
| SCHEMBL12578366 | 0.79 | SMN1; SMN2 (0.32) | TRPV4 | |
| SCHEMBL13262415 | 0.77 | TRPV4 (0.32) | TRPV4NR1I2CYP2C9MLYCD | |
| SCHEMBL18639231 | 0.74 | TRPV4 (0.68) | TRPV4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10925876-B2 | Methods for using triazolo-pyrazinyl soluble guanylate cyclase activators in fibrotic disorders | MERCK SHARP & DOHME CORP. (US) | 2021-02-23 | — | — | US | disclosed |
| US-20190282579-A1 | METHODS FOR USING TRIAZOLO-PYRAZINYL SOLUBLE GUANYLATE CYCLASE ACTIVATORS IN FIBROTIC DISORDERS | MERCK SHARP & DOHME CORP. (US) | 2019-09-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190282579-A1 | METHODS FOR USING TRIAZOLO-PYRAZINYL SOLUBLE GUANYLATE CYCLASE ACTIVATORS IN FIBROTIC DISORDERS | GUCY1B1, GUCY1A1, GUCY1A2 | TRPV4 3484/4885NR1I2 2268/4885CYP2C9 3159/4885 |
| US-10925876-B2 | Methods for using triazolo-pyrazinyl soluble guanylate cyclase activators in fibrotic disorders | GUCY1B1, GUCY1A1, GUCY1A2 | TRPV4 3484/4885NR1I2 2268/4885CYP2C9 3159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.